Selected Stock Price Target News — July 16, 2026

BlackRock ($BLK), Elevance Health ($ELV), and Cintas ($CTAS) all reported earnings on July 15. All three beat. The day after, the analysts moved. BlackRock drew three fresh target changes, one of them an upgrade. Elevance split the desks, with one firm cutting and another raising. Cintas got a clean upgrade to Buy.

Record $15.3 Trillion In Assets Pulls A Fresh JPMorgan Upgrade On BlackRock

BlackRock is the largest money manager in the world. It runs about $15.3 trillion for its clients. That total is a record. Most of what it earns is a management fee. The fee is a small slice of the money it holds. When client assets rise, that fee rises too. So the size of the pile drives the income. But the model cuts both ways. When markets drop, the fee shrinks with them.

Where BlackRock’s Money Comes From

Most of BlackRock’s revenue comes from base fees, the management fee it charges on the $15.3 trillion it runs. That line brought in $5.7 billion in the second quarter, 81% of total revenue, up 29% from a year earlier. Securities lending, a smaller related fee, added $239 million, up from $171 million a year ago. The biggest single product line inside that base-fee number is iShares, BlackRock’s exchange-traded funds. Index funds and active funds sit alongside them. BlackRock also earns performance fees when its funds beat a benchmark. Those totaled $305 million in the quarter. $115 million of that came from HPS, the private-credit lender BlackRock bought earlier this year, alongside Global Infrastructure Partners and the data firm Preqin.

The Rest Of The Business

BlackRock also rents out software. The platform is called Aladdin. Banks and other managers pay to run their portfolios on it. That technology and subscription revenue grew 13% from a year earlier, while distribution fees, paid by the banks and brokerages that sell BlackRock’s funds to their own clients, added $395 million, up from about $320 million a year ago. Total revenue for the quarter was $7.08 billion, up 31% from $5.42 billion in the second quarter of 2025.

The Quarter Behind The Move

BlackRock reported on July 15. Adjusted earnings came in at $13.91 a share. Analysts had looked for $12.57. So the beat was $1.34. Revenue grew at a double-digit rate from a year earlier. New client money set a quarterly record. Assets under management reached an all-time high. The board also raised the quarterly buyback to $550 million.

Three Desks Move The Same Morning

Three firms changed their targets on July 16. Kenneth Worthington at JPMorgan upgraded BlackRock to Overweight from Neutral. His target jumped to $1,364 from $1,165, the largest target increase of the three. Worthington has reached 70.88% of his past targets. He had held a Neutral rating for months. Now he’s Overweight. Benjamin Budish at Barclays held his Overweight. He pushed his target to $1,450. That’s the highest on Wall Street. Budish was already bullish. So his raise mostly extended a view he already held. Craig Siegenthaler at BofA Securities kept his Buy. He raised his number to $1,320. AnaChart records 16 analysts on the stock over the last twelve months. Their average target is $1,297.04. The high sits at $1,514. Across those 16, targets have been reached 75.67% of the time. Nine of every ten current ratings are Buy.

A Raised Full-Year Outlook Splits The Desks On Elevance Health

Elevance Health is a health insurer. It covers roughly 105 million people. The model is simple to describe. Employers and governments pay Elevance monthly premiums. Elevance then pays its members’ medical claims. It keeps whatever is left over. That margin is thin, so cost control is the whole game.

Where Elevance’s Revenue Comes From

The company splits into two segments. Health Benefits sells the insurance plans and collects the premiums. It brought in $42.7 billion in the second quarter, up 2.7% from a year earlier, while Carelon, which sells pharmacy benefits and other health services including to outside health plans, brought in $19.2 billion, up 6%, the faster-growing of the two. Some of Carelon’s revenue comes from services it sells to Elevance’s own Health Benefits arm, which is why the two segments together add up to more than the company’s total operating revenue of $49.83 billion for the quarter.

Why The Cost Trend Matters

Managed care had a hard 2026. Medical costs ran hotter than insurers had planned. Members used more care than the models assumed. That pressure hit profits across the whole group. Elevance also sits under a regulatory cloud. Federal Medicare rules have kept some investors wary. So every quarter gets read closely for the cost trend.

The Print That Beat And Raised

Elevance reported on July 15. Adjusted earnings were $7.45 a share. The estimate was $6.21. It cleared the mark by $1.24. Management also lifted its full-year outlook. It now guides to adjusted earnings of at least $27.00 a share. Even so, the desks landed in different places.

One Desk Cuts, One Desk Raises

Two firms moved on July 16, in opposite directions. Andrew Mok at Barclays kept his Overweight rating. But he cut his target to $457 from $480. Mok has reached 61.47% of his past targets. Michael Ha at Baird went the other way. He stayed Neutral and raised his target to $393 from $331. The split didn’t start this week. Meanwhile, the bullish side had been building. In the days before the print, three more desks lifted their targets. They landed between $465 and $492. AnaChart records 19 analysts on Elevance over the last twelve months. Their average target is $418.39. On this name, targets have been reached just 46.19% of the time. That’s the lowest materialized rate of the three stocks here.

A Record $11.26 Billion Year Turns BofA Bullish On Cintas

Cintas rents work uniforms. That’s the core of the company. It also supplies floor mats, mops, restroom products, and first aid kits. More than a million businesses pay it. Most of the money is a recurring rental fee. Still, some revenue comes from one-time direct sales. A customer signs up and gets a weekly route. A Cintas truck swaps dirty items for clean ones each week. That route model brings steady, repeat revenue. The largest segment is Uniform Rental and Facility Services. Within it, uniforms make up 47% of sales. Dust control mats add 20%. Hygiene products are 16%, and linen is 11%. In fiscal 2026, total revenue reached $11.26 billion.

The Year That Just Closed

Cintas runs on a May fiscal year. It reported the fourth quarter on July 15. Quarterly revenue was $2.91 billion, up 8.9% from a year before. Uniform Rental and Facility Services, the core segment, brought in $2.20 billion of that, up 8.2%, while First Aid and Safety Services, the fastest-growing segment, added $368.1 million, up 13.5%. Fire protection and direct uniform sales, grouped as one reporting segment, brought in $339.4 million, up 8.6%. Within that, fire protection revenue grew while direct uniform sales fell 4%. Earnings came in at $1.29 a share. The estimate was $1.24. For the full year, adjusted earnings were $4.94 a share. Cintas is also buying a rival, UniFirst. That deal is still moving through approvals.

BofA Flips Its Own Call

Curtis Nagle at BofA made the move on July 16. He upgraded Cintas to Buy from Neutral. His target rose to $230 from $200. The flip stands out for one reason. Nagle himself rated the stock Neutral in late June. His target back then was $200. Two weeks and one earnings report later, he turned bullish. Nagle has reached 68.82% of his past targets. His fresh $230 sits above the pack. AnaChart records 10 analysts on Cintas over the last twelve months. Their average target is $218.30. Most of them still say Hold. Only about a quarter of the ratings are Buy. But Nagle just crossed into that smaller Buy camp. So the upgrade puts him against the crowd on the name.

July 16 brought moves on all three names. At JPMorgan, Kenneth Worthington upgraded BlackRock. Benjamin Budish at Barclays and Craig Siegenthaler at BofA Securities raised their targets. On Elevance Health, Andrew Mok trimmed his number while Michael Ha at Baird raised his. Curtis Nagle upgraded Cintas. AnaChart keeps score on every one of these calls over time. So the track record grows with each new target. The database holds 661,383 price targets and 759,654 ratings from 7,191 analysts across 9,686 tickers and 424 brokers. The full history sits in the analyst price target dataset.